CRISPR Therapeutics names Andrew Silver CFO, Raju Prasad resigns

CRISPR Therapeutics AG disclosed in an 8-K dated October 19, 2026, that it had promoted Andrew J. Silver, currently the Company's SVP, Finance, to be the Company's Chief Financial Officer effective immediately.¹ Silver will also serve as the company's principal financial officer and principal accounting officer.¹

Silver, aged 42, has served as the Company's Senior Vice President of Finance since January 2025, and he joined the Company in October 2018, holding roles covering strategic finance, treasury, financial planning and analysis, accounting and reporting, tax and financial operations.¹ Before joining the company, he spent more than 10 years at Ernst & Young LLP, most recently as a Senior Manager in Assurance Services, where he became a Certified Public Accountant.¹

In connection with the promotion, the Company's wholly owned subsidiary, CRISPR Therapeutics, Inc, entered into an Employment Agreement with Silver, dated October 19, 2026.¹ Under the agreement, Silver will receive an annual salary of $515,000 and will be eligible for a target bonus of 45% of his annual base salary.¹ He will also receive a one-time grant of 25,000 restricted stock units in connection with his promotion to Chief Financial Officer,¹ which will vest in full on the second anniversary of the grant date, subject to his continued service.¹

The agreement also includes severance provisions: if terminated without Cause or if Silver resigns for Good Reason, the terminating party must give six months' notice,¹ and if such termination occurs within 12 months following a Change in Control, the Notice Period becomes 12 months and his equity awards will vest.¹

Separately, on October 19, 2026, Raju Prasad, Ph.D. informed the Company he would be stepping down to pursue external opportunities and resigned as Chief Financial Officer.¹ The company said his decision was not the result of any disagreement over operations, policies, or financial practices.¹ Prasad is expected to remain employed by CRISPR Inc. until a date on or before November 30, 2026.¹